STAT+: FDA’s warning to J&J’s Abiomed signals a crackdown on digital health tools
STAT
OCTOBER 16, 2023
The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed. billion, sells devices for heart failure patients as well as patient monitoring software.
Let's personalize your content